India, Sept. 21 -- PharmEasy-owned diagnostic chain Thyrocare Technologies has approved the sale of its entire stake in wholly owned subsidiary Nueclear Healthcare Ltd (NHL) to Trovera Healthcare for about Rs.141.4 Cr in a cash-and-stock deal.

The transaction will see Thyrocare transfer 1.11 Cr equity shares, representing 100% of NHL's issued and paid-up equity share capital, to Trovera.

Trovera will pay Rs.81.9 Cr in cash and allot 42,500 CCPS worth Rs.59.5 Cr to Thyrocare. The CCPS, priced at Rs.14,000 apiece, will represent approximately 4.5% of Trovera's share capital and will be convertible into equity shares in a 1:1 ratio.

Trovera was incorporated in June and was founded by Surana Group of Hospitals CEO Dr Prince Surana. The com...